Research
Hormonal
Patients treated with GLP-1 RAs experienced a lower occurrence of sight-threatening complications, including blindness (HR, 0.77; 95% CI, 0.73-0.82).
GLP-1 RAs may help reduce the risk of severe ocular complications in T2D patients.
StrongSupportsmedium confidence
GLP-1 RAs were associated with a lower occurrence of blindness (HR, 0.77; 95% CI, 0.73-0.82).
Why this rating
Based on a large retrospective cohort study design.
Source
GLP-1 Receptor Agonists and Sight-Threatening Ophthalmic Complications in Patients With Type 2 Diabetes
David J. Ramsey et al. · JAMA Network Open · 2025
cohort · n=185066Cited 41×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →